No increased risk of nephrotoxicity associated with 5‐aminosalicylic acid in IBD: a population‐based cohort and nested case‐control study

• DOI: 10.1111/apt.15408
• Publication Date: 2019-07-12T10:39:24Z
• Authors: Vipul Jairath; Suvi R. K. Hokkanen; Leonardo Guizzetti; Naomi Boxall; Sarah Campbell‐Hill; Haridarshan Patel
• Keywords: Nephrotoxicity; Concomitant; Nested case-control study

Summary Background There is conflicting evidence about nephrotoxicity risk associated with 5‐aminosalicylates for treatment of IBD. Aims To determine population‐based temporal trends and estimated 5‐aminosalicylate use ulcerative colitis (UC) Crohn's disease (CD). Methods Retrospective cohort nested case‐control study, using the Health Improvement Network primary care database linked to hospital discharge coding patients in England, 1996‐2017. Nephrotoxicity analysis was a first recorded renal impairment diagnosis adjusted key variables assessed between 2008 2017. Results A total 35 601 prevalent UC or CD were included. The proportion prescribed fell from 83% 1996‐1999 71% 2012‐2015 64% 45% patients. Thirty per cent had prolonged use. Between 2017, incident rate similar stable (12.6/1000 person‐years) (10.9/1000 Multivariate showed no association current prescription patients, comparing ≤ 30 days prior index vs 31‐≤180 days. However, active disease, duration, concomitant cardiovascular diabetes nephrotoxic drug independently development CD. Conclusions Despite paucity their benefit, approximately half (30% therapy). rare this patient cohort, not use, but rather status, comorbidity drugs.